Method of dephosphorylating an endotoxin in vivo with alkaline phosphatase
US6290952A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 10, 1996 |
| Grant date | Sep 18, 2001 |
| Priority date | — |
| Expiry date | Apr 10, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to pharmaceutical compositions suitable for treating or curing clinical complications mediated by endotoxin, including sepsis. The compositions contain components suitable for detoxifying endotoxin rendering it less deleterious to mammals such as humans, in particular to patients with reduced host-defence resistance. The invention also relates to pharmaceutical compositions suitable for stimulating bone formation, e.g. for mending broken bone or for prophylaxis or therapy of metabolic bone diseases such as osteoporosis and osteomalacia and pharmaceutical compositions for decreasing or inhibiting undesired bone formation. The pharmaceutical compositions according to the invention are directed at modulating phosphatase activity in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.